NCT04178993View on ClinicalTrials.gov

Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

May 5, 2021

Study Completion Date

May 5, 2021

Conditions
Methamphetamine Use Disorder
Interventions
DRUG

Methamphetamine

In each arm, subjects will receive doses of methamphetamine.

DRUG

Methylphenidate

In each arm, subjects will receive methylphenidate capsules.

DRUG

Placebo oral capsule

In each arm, subjects will receive placebo capsules.

DRUG

Duloxetine

Subjects will receive duloxetine capsules in the duloxetine arm.

Trial Locations (2)

40507

University of Kentucky, Lexington

40536

University of Kentucky Medical Center, Lexington

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Craig Rush

OTHER

NCT04178993 - Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine] | Biotech Hunter | Biotech Hunter